Search research articles
Contact Us
Filters
Showing results (111-120 of 121) with videos related to
Page
of 13
Sort By:
Urologic Oncology
|
August 22, 2025
Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy
C N Sternberg, P Squifflet, E D Saad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 20, 2024
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
Y Loriot, D P Petrylak, A Rezazadeh Kalebasty, et al.
ESMO Open
|
May 13, 2021
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort
G Fornarini, S E Rebuzzi, G L Banna, et al.
ESMO Open
|
August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R de Wit, C Wülfing, D Castellano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 11, 2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
T Powles, S Tagawa, C Vulsteke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2019
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2017
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Y Fradet, J Bellmunt, D J Vaughn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 26, 2017
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer
C J Pezaro, A Omlin, K Mastris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 5, 2015
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 121) with videos related to
Sort By:
Page
of 13
Urologic Oncology
|
August 22, 2025
Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy
C N Sternberg, P Squifflet, E D Saad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 20, 2024
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
Y Loriot, D P Petrylak, A Rezazadeh Kalebasty, et al.
ESMO Open
|
May 13, 2021
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort
G Fornarini, S E Rebuzzi, G L Banna, et al.
ESMO Open
|
August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R de Wit, C Wülfing, D Castellano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 11, 2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
T Powles, S Tagawa, C Vulsteke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2019
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2017
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
A Bamias, K Tzannis, L C Harshman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Y Fradet, J Bellmunt, D J Vaughn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 26, 2017
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer
C J Pezaro, A Omlin, K Mastris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 5, 2015
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, et al.
Page
of 13